[ad_1]
The first shot of Modernof (NASDAQ: ARNM) The two-dose coronavirus vaccine has not been in the arms of the millions who will eventually receive it, but the company is already planning to assess the effectiveness of a booster.
In a presentation at this year’s annual conference JP Morgan Healthcare Conference, Moderna announced plans to do so in a clinical trial involving participants in previous studies of the vaccine, mRNA-1273. He has already started contacting potential participants and plans to start the study in July.
Image source: Getty Images.
“From what we’ve seen so far, I think we expect the vaccination to last at least a year,” Moderna chief medical officer Tal Zaks told the conference. “To the extent that you need a reminder, we will make a recommendation based on the data, and that will require us to obtain the data.”
In the planned study, Moderna will attempt to determine the level of immune response still generated by the booster, CEO Stéphane Bancel said at the event.
Now is the time for a follow-up study, as participants in the vaccine’s first clinical trials approach their first anniversary of receiving the booster. They received the first shot in mid-March 2020.
Moderna is one of two coronavirus vaccines that have been granted emergency use approval by the United States Food and Drug Administration. However, deployments of mRNA-1273 and Pfizer/BioNTechSimilar two-shot BNT162b2s were slow. The number of patients who received the first dose remains extremely low.
[ad_2]
Source link